Is combined therapy of Tafamidis and Vutrisiran recommended for cardiac amyloidosis ?
April 28
Yes, vutrisiran (Amvuttra) has shown meaningful improvements for people with cardiac amyloidosis. In March 2025, it received FDA approval specifically for treating transthyretin amyloid cardiomyopathy (ATTR-CM), adding to its earlier approval for hereditary amyloidosis with nerve damage.
Clinical trials have shown some Show Full Answer
Yes, vutrisiran (Amvuttra) has shown meaningful improvements for people with cardiac amyloidosis. In March 2025, it received FDA approval specifically for treating transthyretin amyloid cardiomyopathy (ATTR-CM), adding to its earlier approval for hereditary amyloidosis with nerve damage.
Clinical trials have shown some impressive results across several key areas:
- Survival — more patients on vutrisiran survived compared to those on placebo
- Hospitalizations — fewer hospital visits were needed
- Physical function — patients could walk farther
- Quality of life — overall wellbeing improved significantly It's worth knowing that vutrisiran works by reducing the liver's production of the problematic TTR protein by around 80–85%. This helps slow the buildup of amyloid deposits in the heart.
However, it's important to understand that while it slows disease progression significantly, it doesn't reverse existing damage or completely stop deposits. This is why early diagnosis and starting treatment sooner rather than later can make a real difference.
As always, a conversation with your care team is the best way to find out if vutrisiran is the right fit for your specific situation.
April 28
Join
Your Privacy Choices
